论文部分内容阅读
目的探讨多西他赛联合顺铂治疗晚期非小细胞肺癌的临床疗效和不良反应。方法选择阜阳市人民医院收治的晚期非小细胞肺癌患者36例,所有患者第1天均给予多西他赛75 mg/m2,静脉滴注3 h,第2～5天给予顺铂20 mg/m2,静脉滴注,21 d为1个周期,化疗2个周期以上,然后按WHO标准评价疗效和不良反应。结果 36例患者均可评价疗效,全组无CR,PR 16例,SD 15例,PD 5例,总有效率(CR+PR)为44.4%。初治组有效率为54.5%,复治组有效率为28.6%,两组间比较差异有统计学意义(P<0.05)。主要的不良反应为骨髓抑制,肌肉酸痛,恶心、呕吐,脱发等,其中白细胞下降发生率为63.9%,肌肉酸痛发生率为41.6%,恶心、呕吐发生率为47.2%,脱发发生率为61.1%,患者均可耐受。结论多西他赛联合顺铂治疗晚期非小细胞肺癌有较好疗效,不良反应轻,值得临床进一步推广应用。
Objective To investigate the clinical efficacy and adverse reactions of docetaxel plus cisplatin in the treatment of advanced non-small cell lung cancer. Methods Thirty-six patients with advanced non-small cell lung cancer admitted to Fuyang People’s Hospital were enrolled. All patients were given docetaxel 75 mg / m2 on the first day, 3 h after intravenous drip, and 20 mg / m2, intravenous drip, 21 d for a period of more than 2 cycles of chemotherapy, and then evaluated according to WHO standards of efficacy and adverse reactions. Results All 36 patients were eligible for evaluation. There were 16 patients without CR, PR, 15 with SD and 5 with PD. The total effective rate (CR + PR) was 44.4%. The effective rate was 54.5% in primary treatment group and 28.6% in retreatment group, with significant difference between the two groups (P <0.05). The main adverse reactions were myelosuppression, soreness, nausea, vomiting and alopecia. Incidence of leukopenia was 63.9%, muscle soreness was 41.6%, nausea and vomiting was 47.2%, hair loss was 61.1% , Patients can be tolerated. Conclusion Docetaxel combined with cisplatin in the treatment of advanced non-small cell lung cancer has better curative effect and less adverse reactions, which deserves further clinical application.